Literature DB >> 24350809

Host immunological response and factors associated with clinical outcome in patients with the novel influenza A H7N9 infection.

Z Shen1, Z Chen, X Li, L Xu, W Guan, Y Cao, Y Hu, J Zhang.   

Abstract

In March 2013, an influenza outbreak caused by the novel avian-origin H7N9 influenza A virus emerged in eastern China and had caused 43 fatalities by 31 July 2013, although the basis for disease pathogenesis still remains unclear. To assess the immunological and viral factors associated with disease severity, viral RNA and inflammatory cytokines were quantified for 18 H7N9 patients in Shanghai, China. Detailed clinical information was collected and clinical laboratory investigations were performed for all patients. H7N9 infection is characterized by high pharyngeal virus load and frequent detection of viral RNA in blood. High pharyngeal virus load persisted through the first 10 days of antiviral therapy in fatal cases. Genetic characterization of the H7N9 virus revealed an Arg292Lys mutation in the neuraminidase gene associated with oseltamivir-resistance. Pronounced lymphopenia and high chemokine and cytokine levels were observed in H7N9-infected patients, particularly in those where disease was fatal. Serum levels of interleukin-6 (IL-6), IL-8 and macrophage inflammatory protein-1β in our subjects also correlated positively with pharyngeal virus load. Lymphocyte counts <0.5 × 10(9)  cells/L, and serum IL-6 >97 pg/mL, IL-8 >40 pg/mL and C-reactive protein >90 mg/L were identified as being connected with adverse clinical outcome through univariate logistic analysis. Significant survival differences were also observed between patients with serum C-reactive protein <90 mg/L or creatinine <90 μmol/L and those with higher levels. Our data demonstrated that high viral load, and the resulting intense inflammatory responses, played an important role in H7N9 pathogenesis. Though immunomodulatory treatment has potential benefits, the focus of clinical management should be on preventing the intense cytokine response by early diagnosis and effective antiviral treatment.
© 2013 The Authors Clinical Microbiology and Infection © 2013 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Keywords:  Avian influenza A H7N9; clinical laboratory features; clinical outcome; innate immunity; viral dynamics

Mesh:

Substances:

Year:  2014        PMID: 24350809     DOI: 10.1111/1469-0691.12505

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  20 in total

Review 1.  Pandemic potential of avian influenza A (H7N9) viruses.

Authors:  Tokiko Watanabe; Shinji Watanabe; Eileen A Maher; Gabriele Neumann; Yoshihiro Kawaoka
Journal:  Trends Microbiol       Date:  2014-09-25       Impact factor: 17.079

2.  A(H7N9) virus results in early induction of proinflammatory cytokine responses in both human lung epithelial and endothelial cells and shows increased human adaptation compared with avian H5N1 virus.

Authors:  Hui Zeng; Jessica A Belser; Cynthia S Goldsmith; Kortney M Gustin; Vic Veguilla; Jacqueline M Katz; Terrence M Tumpey
Journal:  J Virol       Date:  2015-02-11       Impact factor: 5.103

3.  Enhanced natural killer-cell and T-cell responses to influenza A virus during pregnancy.

Authors:  Alexander W Kay; Julia Fukuyama; Natali Aziz; Cornelia L Dekker; Sally Mackey; Gary E Swan; Mark M Davis; Susan Holmes; Catherine A Blish
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-22       Impact factor: 11.205

4.  An overview of the characteristics of the novel avian influenza A H7N9 virus in humans.

Authors:  Kei-Xian Tan; Sabrina A Jacob; Kok-Gan Chan; Learn-Han Lee
Journal:  Front Microbiol       Date:  2015-03-05       Impact factor: 5.640

5.  The Serum Profile of Hypercytokinemia Factors Identified in H7N9-Infected Patients can Predict Fatal Outcomes.

Authors:  Jing Guo; Fengming Huang; Jun Liu; Yu Chen; Wei Wang; Bin Cao; Zhen Zou; Song Liu; Jingcao Pan; Changjun Bao; Mei Zeng; Haixia Xiao; Hainv Gao; Shigui Yang; Yan Zhao; Qiang Liu; Huandi Zhou; Jingdong Zhu; Xiaoli Liu; Weifeng Liang; Yida Yang; Shufa Zheng; Jiezuan Yang; Hongyan Diao; Kunkai Su; Li Shao; Hongcui Cao; Ying Wu; Min Zhao; Shuguang Tan; Hui Li; Xiaoqing Xu; Chunmei Wang; Jianmin Zhang; Li Wang; Jianwei Wang; Jun Xu; Dangsheng Li; Nanshan Zhong; Xuetao Cao; George F Gao; Lanjuan Li; Chengyu Jiang
Journal:  Sci Rep       Date:  2015-06-01       Impact factor: 4.379

6.  Protective immunity and safety of a genetically modified influenza virus vaccine.

Authors:  Rafael Polidoro Alves Barbosa; Ana Paula Carneiro Salgado; Cristiana Couto Garcia; Bruno Galvão Filho; Ana Paula de Faria Gonçalves; Braulio Henrique Freire Lima; Gabriel Augusto Oliveira Lopes; Milene Alvarenga Rachid; Andiara Cristina Cardoso Peixoto; Danilo Bretas de Oliveira; Marco Antônio Ataíde; Carla Aparecida Zirke; Tatiane Marques Cotrim; Érica Azevedo Costa; Gabriel Magno de Freitas Almeida; Remo Castro Russo; Ricardo Tostes Gazzinelli; Alexandre de Magalhães Vieira Machado
Journal:  PLoS One       Date:  2014-06-13       Impact factor: 3.240

7.  Factors associated with clinical outcome in 25 patients with avian influenza A (H7N9) infection in Guangzhou, China.

Authors:  Hui Wang; XinCai Xiao; Jianyun Lu; Zongqiu Chen; Kuibiao Li; Hui Liu; Lei Luo; Ming Wang; ZhiCong Yang
Journal:  BMC Infect Dis       Date:  2016-10-03       Impact factor: 3.090

8.  Boolean Modeling of Cellular and Molecular Pathways Involved in Influenza Infection.

Authors:  Christopher S Anderson; Marta L DeDiego; David J Topham; Juilee Thakar
Journal:  Comput Math Methods Med       Date:  2016-02-14       Impact factor: 2.238

Review 9.  Modulating the Innate Immune Response to Influenza A Virus: Potential Therapeutic Use of Anti-Inflammatory Drugs.

Authors:  Irene Ramos; Ana Fernandez-Sesma
Journal:  Front Immunol       Date:  2015-07-20       Impact factor: 7.561

10.  Profiles of acute cytokine and antibody responses in patients infected with avian influenza A H7N9.

Authors:  Rui Huang; Lu Zhang; Qin Gu; Yi-Hua Zhou; Yingying Hao; Kui Zhang; Yong Liu; Danjiang Dong; Shixia Wang; Zuhu Huang; Shan Lu; Chao Wu
Journal:  PLoS One       Date:  2014-07-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.